艾普拉唑治疗反流性食管炎临床效果观察及药物经济学分析

Clinical efficacy and pharmacoeconomics of ilaprazole in the treatment of reflux esophagitis

目的 对艾普拉唑治疗反流性食管炎的临床效果及药物经济学进行分析.方法 选取80例确诊为反流性食管炎患者作为研究对象.按照随机数字表法分为观察组和对照组,每组各40例,观察组给予艾普拉唑治疗,剂量为10 mg/d；对照组给予埃索美拉唑治疗,剂量为40 mg/d.两组均治疗8周后,对两组患者临床疗效及治疗费用进行比较,探讨艾普拉唑治疗反流性食管炎的临床效果及药物经济学.结果 治疗8周后,观察组患者症状评分（0.7±0.3）分,与治疗前的（3.1±0.8）分差异有统计学意义（t=16.7,P＜0.01）.对照组患者治疗后症状评分（0.4±0.3）分较治疗前（3.2±0.9）分也显著降低,差异有统计学意义（t =18.6,P＜0.01）；但两组间差异无统计学意义（t=0.00,P＞0.05）.观察组显效35例,有效2例,总有效率为92.5％；对照组显效36例,有效2例,总有率为95.0％；两组总有效率差异无统计学意义（x2=0.21,P＞0.05）.治疗8周后内镜检查发现,观察组痊愈34例,好转2例,总有效率为90.0％；对照组痊愈35例,好转2例,总有率为92.5％；两组内镜下总有效率差异无统计学意义（x2=0.15,P＞0.05）.两组治疗费用差异无统计学意义（t =0.99,P＞0.05）.结论 艾普拉唑治疗反流性食管炎临床效果与埃索美拉唑相似,治疗费用相当,是治疗反流性食管炎的有效药物.

Objective To analyze the clinical effects and pharmacoeconomics of ilaprazole in the treatment of reflux esophagitis. Methods 80 reflux esophagitis patients were selected as research subjects,who were divided in- to observation group and the control group, each group 40 cases according to the random number table. The observation group was given ilaprazole treatment, the dose for the 10mg/d; the control group received esomeprazole treatment, the dose for the 40mg/d. After 8 weeks of treatment, the clinical efficacy and cost of treatment of the two groups were com- pared. The ilaprazole clinical efficacy and pharmacoeconomics treatment of reflux esophagitis was explored. Results （ 1 ） After 8 weeks of treatment, symptom scores in patients of thc observation group （0.7 ± 0.3 ） point, compared with before treatment（3.1 ±0.8 ） point was significantly lower, the difference was statistically significant （ t = 15.7, P 〈 0. 01 ）. The control group patients after symptom score （0.4± 0：3 ） than before treatment （ 3.2 ± 0.9 ） was also signif- icantly reduced, the difference was statistically significant（ t = 18.6, P 〈 0.01 ） ;there was no statistically significant in score after 8 weeks of treatment between the two groups（t =0.00,P 〉0.05）. 35 cases in the observation group hadmarkedly effectiveness in 2cases,the total effective rate was 92.5% ;36 cases in control group had markedly effective- ness in 2 cases, the total rate was 95% ;efficiency of treatment of the two groups of patients was compared with that difference was not statistically significant（ x2 =0.21 ,P 〉0.05 ）. 3 ）The analysis found that the observation group 34 cases were cured,improved in 2 cases, total effective rate was 90% ; the control group, 35 cases were cured, 2 cases improved endoscopic efficacy in two groups of patients after 8 weeks of treatment,the total was 92.5% ;4） There was no statistically significant difference in the efficiency of treatment of the two groups （X2 = 0.15 ,P 〉 0.05 ）. The cost of treatment between the two groups was not statistically significant （ t = 0.99,P 〉 0.05 ）. Conclusion Ilaprazole has the similar clinical effect and cost with esomeprazole in the treatment of reflux esophagitis, and ilaprazole is an effec- tive drug for treatment of reflux esophagitis.